RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC increased its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 15,557.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,174,313 shares of the company’s stock after purchasing an additional 1,166,813 shares during the quarter. ADAR1 Capital Management LLC’s holdings in RAPT Therapeutics were worth $1,855,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares during the period. JPMorgan Chase & Co. increased its position in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of RAPT Therapeutics by 401.9% in the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after acquiring an additional 42,636 shares during the period. Medicxi Ventures Management Jersey Ltd acquired a new position in shares of RAPT Therapeutics during the 4th quarter valued at $35,316,000. Finally, Los Angeles Capital Management LLC boosted its position in RAPT Therapeutics by 9.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after purchasing an additional 18,558 shares during the period. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Stock Down 4.5 %

Shares of NASDAQ RAPT opened at $1.06 on Monday. The stock has a market cap of $139.93 million, a P/E ratio of -0.38 and a beta of -0.29. The firm’s 50-day simple moving average is $1.19 and its 200 day simple moving average is $1.43. RAPT Therapeutics, Inc. has a fifty-two week low of $0.79 and a fifty-two week high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, sell-side analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.